The National Comprehensive Cancer Network® (NCCN®) was formed to provide state-of-the-art cancer treatment information in easy-to-understand language for patients and caregivers. The NCCN Guidelines for Patients™, based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™), are designed to help you when you talk with your doctor about treatment options.Here is a link to
Sunday I wrote a brief article about Michael Tomasson, a physician-scientist based at Washington University in St. Louis: Researchers Continue To Isolate & Interpret Genetic Information Relevant To Treating Multiple Myeloma.Here is a link to a follow-up video about Dr. Tomasson and his research: Major progress on Multiple Myeloma Program Project Grant (PPG). One-year planning
Yesterday I shared an important article about how patients often don't hear what their oncologist is saying: Big Mistake: Most Patients Don't Listen Carefully To Their Oncologists.The bottom line: “In several key areas, information was either missing or had been explained but was interpreted incorrectly by patients,” they said. Discussion of prognosis was a frequent
Monday I revealed we had added a new, multiple myeloma clinical trial feature to my home page.More good news today: http://www.multiplemyelomablog.com/ is syndicated! TrialX, the same company which developed the clinical trial locator for us and the Muliple Myeloma Research Foundation, is running my articles daily on their glitzy media site, CureTalk. Their innovative and professionally produced Website
Was Controversy About Secondary Cancer Risk Among Long Term Revlimid Users Reactionary Or Overblown?
A fellow multiple myeloma patient blogger and good friend, Nick van Dyk, shared his views about the recent secondary cancer scare for long term users of Revlimid today: Some thoughts on this Revlimid situation...perhaps a false alarm?Nick lives in California, yet he travels all of the way to Arkansas to see myeloma specialists at UAMS.
Have you noticed anything different about my home page recently? Friday I added a "widget" box in the upper right hand corner of my site to help readers locate clinical trials in their area. To use this new Myeloma Clinical Trial Search Tool, simply type in state and click on the "SHOW" button. It's that
Researchers Continue To Isolate & Interpret Genetic Information Relevant To Treating Multiple Myeloma
Michael Tomasson is a physician-scientist based at Washington University in St. Louis. Here is a post from his research blog about a multiple myeloma genome sequencing project he is working on:Our multiple myeloma whole genome sequencing project is kicking into high gear! The Broad Institute in Boston, our friendly competitor, also has a MM WGS
I am writing this post with an "after Christmas family hangover." I would have gotten to this earlier in the day, but my lovely wife insisted we get an early start.We were off and running with an incredible trip to one of my favorite places in the whole world: Honeymoon Island and Caldesi State Park.
I recently saw a news story about how Bill Gates and Warren Buffet are crisscrossing the globe, meeting with fellow billionaires in an attempt to get them to commit part of their fortunes to help solve the world's problems.Wonderful! I have a suggestion—and it wouldn't take billions: Finance independent research studies about the effectiveness of
Yesterday's post was a bit of a "downer." It focused on the potential conflict of interest many of our myeloma docs face as they are blanketed with research data paid for by drug companies.But the news isn't all bad. Thank God for anti-myeloma drugs which work--if only for a while. And for good insurance, Medicare
I found this update about accelerated approval for carfilzomib online at Pharma Times Online earlier this month:Onyx to seek accelerated approval on carfilzomib Phase IIb results Clinical News - December 09, 2010 by Peter Mansell Onyx Pharmaceuticals plans to file a US New Drug Application “as early as mid-2011” for potential accelerated approval of carfilzomib,
What Our Doctors Read Influences How Patients Are Treated – For Now That Means Using Lots Of Drugs & Invasive, Expensive Transplants
What our doctors read in medical journals and publications which summarize research results and new therapy trends greatly influences how they are likely to act.Case in point: Here is an article from the trade publication, Internal Medicine News about what is soon to be considered the "standard of care" for multiple myeloma patients:ORLANDO – For patients
I just reported some positive news about Revlimid on Sunday, American Society of Clinical Oncology Recognizes Revlimid As One Of The Year's "Most Notable Advances." I should have also mentioned this Wall Street Journal story: Celgene Raises Price Of Blood Cancer Drug Revlimid By 4.5%. It has been an up-and-down month for Revlimid. Lots of positive
Saturday I started sharing some basics for newly diagnosed multiple myeloma patients and caregivers, Tips To Raise Your Multiple Myeloma IQ.We covered the what, how's and why's about interpreting a prognosis, how genetic abnormalities can complicate a diagnosis and understanding median life expectancy. I can't emphasize enough how important it is to get a second opinion
American Society of Clinical Oncology Recognizes Revlimid As One Of The Year’s "Most Notable Advances."
The American Society of Clinical Oncology (ASCO) issues an annual report yearly. Revlimid is prominently mentioned in this years report, published in the Journal of Clinical Oncology, in the "Notable Advances" category. Here is what the report had to say about Revlimid (lenalidomide):Lenalidomide maintenance therapy slows myeloma progression.Multiple myeloma, a cancer of plasma cells in
Friends and business associates often tell me I write like I talk. Good! Because that is what I'm going to do here. I'm going to try and explain the best I can—patient to patient and in my own words—what I think every multiple myeloma patient should know. You are reading my www.multiplemyelomablog.com site now—that's a
Back To Basics: Newly Diagnosed? Need Help Understanding Your Prognosis Or Treatment Options? Let Me Show You Where To Start
The past two weeks have been all about multiple myeloma related research, FDA approvals and hope. Not so much about hope for a cure—we all want that! No, I'm talking about baby steps. Hope that one or more of the new drugs previewed at the American Society of Hematology (ASH) meetings in Orlando, Florida will help
Attention Long Term Revlimid Users: Millennium Pharmaceuticals Working To Develop A New Anti-Leukemia Drug, MLN 4924.
Last week I wrote several articles about the results from two new studies, both finding an 8% risk of developing a secondary cancer in patients who use Revlimid over an extended period of time.At the end of one of the articles I stated:My opinion is this:It seems to me an 8% risk of developing another manageable
It is always interesting to see how the general medical community views multiple myeloma/ASH related news. Here is an article from the well respected Internal Medical News about three Millennium Pharmaceutical studies featuring bortezomib (Velcade) at ASH:Bortezomib-Based Regimens Help Older Patients With Multiple Myeloma By: NEIL OSTERWEIL, Internal Medicine News Digital Network - 12/15/10 Major
Exciting News About New, Easier & Safer Delivery System For Velcade Announced At ASH: Subcutaneous Administration
Almost two years ago, I learned Millennium was working on a new, more convenient way to administer Velcade. Subcutaneous (subq for short) administration--shots given with a small needle just under the skin, often in the belly--would cost less and save nurses and patients time. At ASH, I learned European trials of subq Velcade were moving